Intercept Pharmaceuticals : Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA) - Form 8-K

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid


OCA 25 mg met the agreed primary endpoint of... | July 7, 2022

Related Keywords

,Nareg Sagherian ,Karen Preble ,Exchange Commission ,Linkedin ,Global Corporate Communications ,Intercept Pharmaceuticals Inc ,Twitter ,Securities Exchange ,Nasdaq ,Intercept Announces Positive Data ,New Analysis ,Obeticholic Acid ,Analysis Methodology ,Randomized Global Phase ,Obeticholic Acid Treatment ,Liver Fibrosis ,New Drug Application ,Securities Act ,Securities Exchange Act ,Annual Report ,Quarterly Report ,Executive Director ,Global Investor Relations ,Intercept Pharmaceuticals ,Nc Stock Exchange ,News ,Information ,Press Release ,Intercept ,Nnounces ,Positive ,Data ,N ,Ibrosis ,Ue ,O ,Cash ,Rom ,Few ,Analysis ,F ,Its ,Hase ,Regenerate ,Study ,Beticholic ,Acid ,Ca ,5 ,G ,Pet ,The ,Greed ,Primary ,Ndpoint Icpt Us45845p1084 ,